Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Aegerion Pharmaceuticals (AEGR) to Acquire Myalept from AstraZeneca (AZN) for $325M
November 6, 2014 6:33 AM ESTAegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) entered into a definitive agreement with AstraZeneca (NYSE: AZN) to acquire Myalept, an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.
Myalept is the first and only product approved in the US for the... More
